Enzen试验:Zenith与Endurant腹主动脉覆膜支架治疗肾下腹主动脉髂动脉瘤的结局、内漏与再干预分析
前瞻性连续队列研究纳入2019年1月至2022年12月接受EVAR的156例腹主动脉髂动脉瘤患者,比较Zenith Flex(67例)与Endurant II(89例)的结局。Zenith组晚期内漏、I型内漏、肢体支架闭塞及再干预率均高于Endurant组;720天总生存两组无统计学差异(p=0.09),无再干预率Zenith组82.8% vs Endurant组93.2%(p=0.001)。
要点
- Zenith组晚期内漏发生率34.3%高于Endurant组14.6%(p=0.002),以II型内漏为主。
- Zenith组I型内漏13.4%高于Endurant组3.4%(p=0.002)。
- 720天无再干预率Zenith组82.8%低于Endurant组93.2%(p=0.001)。
核心结论
- 本研究中Zenith支架的内漏、动脉瘤相关死亡、肢体支架闭塞及再干预率高于Endurant II支架。
- 线性回归分析显示内漏、支架类型(Zenith)和肢体支架闭塞与更高的再干预率相关。
研究设计与样本
- 前瞻性连续队列研究,纳入2019年1月至2022年12月接受EVAR的腹主动脉髂动脉瘤患者。
- 共评估156例,Zenith组67例(42.9%),Endurant组89例(57.1%)。
主要发现
- 围手术期死亡5.1%(8例:Zenith组6例 vs Endurant组2例,p=0.054)。
- 急诊修复动脉瘤(扩张或破裂)28例(17.9%),组间无差异。
- 晚期内漏36例(23.1%),Zenith组23例(34.3%)高于Endurant组13例(14.6%,p=0.002),其中II型内漏21例(13.4%)。
- I型内漏12例,Zenith组13.4%高于Endurant组3.4%(p=0.002)。
- 肢体支架闭塞9例(5.8%),Zenith组9%高于Endurant组3.4%(p=0.045);720天总生存Zenith组82.3% vs Endurant组89.1%(p=0.09)。
关键数值与推荐
- 720天无再干预率Zenith组82.8% vs Endurant组93.2%(p=0.001)。
临床怎么用
- 本文提供在EVAR中评估和选择最适合腹主动脉瘤患者支架的机会。
- 作者结论指出Zenith支架的内漏、动脉瘤相关死亡、肢体支架闭塞及再干预率高于Endurant II支架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The main objective of this paper is to analyze the outcomes regarding endoleaks, reinterventions, and death related to aneurysm complications in patients submitted to endovascular repair (EVAR) for abdominal aortoiliac aneurysm (AAA) using Endurant II (Medtronic) and Zenith Flex (Cook) endografts. METHODS: This was a prospective, consecutive cohort study of patients with AAA who underwent EVAR between January 2019 and December 2022. Two groups of patients were evaluated: Group Endurant (patients submitted to EVAR with the use of Endurant II) and Group Zenith (patients submitted to EVAR with the use of Zenith Flex). RESULTS: A total of 156 patients were evaluated. Group Zenith (67 patients, 42.9%) and Group Endurant (89 patients, 57.1%). The perioperative mortality was 5.1%, eight patients (six patients Group Zenith, and two patients Group Endurant, p=0.054). There were 28 patients (17.9%) submitted to urgent repair of the aneurysm (expansion or rupture), with no differences among the groups. There were 36 cases (23.1%) of later endoleak, with a higher incidence in Zenith group (23 patients, 34.3%) than Endurant group (13 patients, 14.6%, p=0.002), most of them Type II endoleak (21 patients, 13.4%). There were 12 cases of Type I endoleak, also with a higher prevalence in Zenith group (13.4%) than Endurant group (3.4%, p=0.002). Moreover, regarding limb graft occlusion (LGO), there were nine patients (5.8%), with a higher prevalence in Zenith group (9%) than Endurant group (3.4%, p=0.045). The overall survival in a Kaplan-Meier at 720 days was 82.3% in the Zenith group and 89.1% in the Endurant group, with no statistical significance among the groups (p=0.09). The freedom from reintervention rates in a Kaplan-Meier at 720 days was 82.8% in the Zenith group and 93.2% in the Endurant group (p=0.001). CONCLUSION: In this present study, Zenith endograft had higher rates of endoleaks, aneurysms related mortality, LGO and reinterventions than patients submitted to Endurant II endografts. The linear regression analysis showed that the presence of endoleaks, type of endograft device (Zenith graft) and limb graft occlusion were related to higher reintervention rates.Clinical ImpactIn this present study, Zenith endograft had higher rates of endoleaks, aneurysms related mortality, limb graft occlusions and reinterventions than patients submitted to Endurant II endografts. The main impact and the innovation that this article provides is an opportunity to evaluate and choose the best endograft suitable for the patient with AAA during EVAR.
引用
- de Athayde Soares R, Portela MVV, Amaro K, et al. The Enzen Trial: Analysis of EVAR Endoprosthesis Zenith and Endurant for Infrarenal Aortoiliac Aneurysms Regarding Outcomes, Endoleaks, and Reinterventions. J Endovasc Ther. 2024. PMID: 39183689. doi:10.1177/15266028241270895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。